GEN İLAÇ VE SAĞLIK ÜRÜNLERİ
SANAYİ TİCARET ANONİM ŞİRKETİ
ACTIVITY REPORT FOR THE PERIOD BETWEEN

01.01.2026 – 31.03.2026

- Unofficial Translation-

1. GENERAL INFORMATION

Activity Period: 01.01.2026 – 31.03.2026

Commercial Title: Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.

Registration Number: Ankara Trade Registry – 131040

Tax Office: Ankara Corporate Tax Office

Tax Number: 391 031 0236

Mersis Number: 0391031023600021

Place of Incorporation: Gen İlaç ve Sağlık Ürünleri Sanayi Ticaret A.Ş. ("GEN", "Company" veya "Gen İlac") is established in Ankara, Türkiye.

Head Office: Mustafa Kemal Mah. 2131 Cad. No:15 İç Kapı No:1 Çankaya / Ankara

Production Facility: ASO 2. And 3. Organize Sanayi Bolgesi Alci OSB Mah. 2013. Cad. No: 24 Sincan/Ankara.

GEN has a total of 10 offices and branches, including 3 in Türkiye located in Ankara, İzmir, and İstanbul, and 7 abroad located in Germany, Azerbaijan (2), Kazakhstan, Uzbekistan, Russia, and Georgia.

Contact Info: 0312 219 62 19 (Center) / 0312 945 14 36 (Production Facility)

Corporate Web Site: https://www.genilac.com.tr/

Independent Audit Company: Denge Ankara Bağımsız Denetim Yeminli Mali Müşavirlik A.Ş.

2. AREA OF OPERATION

The Company's main operation area is production of all kinds of human medicines and health products, trading, import and export of these products. Gen İlaç operates with its medicines especially in the field of treatment of rare diseases and in the elimination of dysfunctions due to these diseases.

3. CAPITAL AND PARTNERSHIP STRUCTURE

The Company accepted authorized capital system according to code numbered 6362 and transmitted to the authorized capital system with the permission of Capital Markets Board of Türkiye dated 08 April 2021 and numbered 19/595.

Between 2024-2028 Our Company's authorized capital limit is TRY 5.000.000.000 and issued capital is TRY 4.500.000.000. TRY 825.000.000 portion of the total capital consist of A group shares and remaining TRY 3.675.000.000 portion consist of B group shares.

In accordance with the Article 7 of our company's Articles of Association A group shareholders have priviledge to promote board member. Also, according to the Article 10 of our company's Articles of Association each A group share has five (5) voting right in general assembly.

Company's capital has been registered and announced on Trade Registry Gazette dated 11 February 2026 and numbered 11520.

The partnership structure of the company as of March 31, 2026 is presented below.

Partner's Name / Title	Capital Amount (TRY)	Ratio (%)
Abidin GÜLMÜŞ	2.994.780.000	66,55
Ali GÖL	300.000.000	6,67
Semra GÜLMÜŞ	56.250.000	1,25
Şükrü TÜRKMEN	22.500.000	0,50
Ömer DİNÇER	22.500.000	0,50
Absel Emlak İnşaat Limited Şirketi	18.750.000	0,42
Public	1.085.220.000	24,11
Total	**4.500.000.000**	**100,00**

4. BOARD OF DIRECTORS AND SENIOR MANAGEMENT

Board Member	Title / Position
Abidin GÜLMÜŞ	Chairman of the Board of Directors & General Manager
Şükrü TÜRKMEN	Vice Chairman of the Board of Directors
Ali GÖL	Board of Directors Member
Tolga KIZILTAN	Board of Directors Member (Independent)
Bernay ÖZAVCI	Board of Directors Member (Independent)

Board Member	Title / Position
Ömer DİNÇER	Deputy General Manager, Administrative Affairs
Selçuk Deniz KARAGÜLLE	Deputy General Manager, Global Sales & Marketing
Yağmur Selin GÜLMÜŞ KOLAY	Deputy General Manager, Strategy & Corporate Development
Nadir ULU	Deputy General Manager, R&D & Clinical Operations
Eda GÜLMÜŞ DEMİR	Deputy General Manager, Foreign Trade
Mustafa GÜRCAN ÜSGÜLEN	Deputy General Manager, Technical Operations

5. SUBSIDIARIES AND AFFILIATED COMPANIES

Affliated Companies ("Group")

GEN forms a Group together with its affiliated companies, detailed below.

Affiliated Companies	Activity Location	Main Activity
Genject Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş.	Türkiye	Syringa Production and Sales
Elixir İlaç Araştırma Geliştirme A.Ş.	Türkiye	Human Drugs R&D
Gen Ilac Germany GMBH	Germany	Drug Marketting and Sales
Gen Pharma Caucasus Manufacturing Operations MMC	Azerbaijan	Pharmaceutical Production

Genject Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş. ("Genject") was founded in 2010 and Gen İlaç ve Sağlık Ürünleri A.Ş. has 96,40% shares in Genject. Genject manufactures its own brand Genject disposable hypodermic syringes in Türkiye in accordance with CE standards.

Elixir İlaç Araştırma Geliştirme A.Ş. ("Elixir") was founded in 2014 and Gen İlaç ve Sağlık Ürünleri A.Ş. has 95,00% shares in Elixir. Elixir conducts R&D studies on the development of new and generic medicine products and production processes in accordance with the standards of the «European Medicine Agency (EMA)» and the «United States Food and Drug Administration (USFDA)».

Gen Ilac Germany GMBH ("Gen Germany") was founded in 2021 and deals with sales and marketting activities of drugs produced by GEN in Europe.

Gen Pharma Caucasus Manufacturing Operations MMC ("GEN Caucasus") was established in 2023, and GEN is a 66.00% partner. GEN Caucasus was established with the aim of establishing a pharmaceutical manufacturing facility in Azerbaijan and selling and marketing the products to be produced in this facility. Currently, construction work of the manufacturing facility continues.

Subsidiaries	Activity Location	Main Acivity	Share Ratio
Stimusil Inc.	USA	Medical Device Development	19,30
RS Araştırma Eğitim Danışmanlık İlaç Sanayi ve Ticaret A.Ş.	Türkiye	Drug Research and Development	13,65
Galventa AG	Switzerland	Drug and Food Supplement Research and Development	4,41
Neo Auvra Dijital Sağlık ve Biyonik Teknolojileri ve Hiz. San. ve Tic. A.Ş.	Türkiye	Biotechnological Medical Device Research and Development	35,15
Invios Holding AG	Austria	Precision Cancer Immunotherapies	0,98
H2O Bilişim Yazılım Elektronik Sağlık Hizmetleri Sanayi ve Türk Ticaret A.Ş.	Türkiye	Digital Health Technologies	10,00
Jaguar Health Inc.	USA	Drug Research and Development	0,09

6. MAIN FINANCIAL INDICATORS

Sales

As of 31.03.2026 according to the financial statement prepared compliant with TAS 29 total revenue of the company is TRY 6.624.045.531



Distribution of Sales

The comparative distribution of GEN's sales for the first quarters of 2024, 2025 and 2026 is presented below.

Sales (TRY)*	Q1/2024	Q1/2025	Q1/2026
NPP Drugs	1.292.821.895	1.411.000.702	2.720.108.891
Imported Registered Drugs	1.346.670.390	1.852.395.497	2.660.141.183
Production Registered Drugs	107.524.944	162.960.118	184.977.516
Exported Drugs	208.808.900	290.797.246	389.717.261
Other (Medical)	-	-	466.086.952
Total Sales	**2.955.826.129**	**3.717.153.563**	**6.421.031.801**

**These values are calculated based on the invoice amounts for the products sold by the company, and TAS 29 Financial Reporting Standards in High Inflation Economies has not been applied.*

A comparative analysis of the first-quarter sales performance for the years 2024, 2025, and 2026 is presented below.



***Sales in the Other (Medical) category were recorded for the first time in the first quarter of 2026, amounting to TRY 466.086.951,71.*

Sales (Boxes)	Q1/2024	Q1/2025	Q1/2026
NPP Drugs	41.304	28.130	43.657
Imported Registered Drugs	131.777	182.347	210.186
Production Registered Drugs	424.522	306.924	549.015
Exported Drugs	945.231	798.421	793.952
Other (Medical)	-	-	1.888
Total Sales	**1.542.834**	**1.315.822**	**1.598.698**

A comparative chart regarding the first quarter sales* for the years 2024, 2025 and 2026 is presented below.



****Sales in the Other (Medical) category were recorded for the first time in the first quarter of 2026, totaling 1.888 boxes*

Distribution of Sales

As of 31.03.2026, the breakdown of sales by product group is presented in the chart below.



**TAS 29 Financial Reporting in Hyperinflationary Economies has not been applied.*
***1.888 boxes = 0.12%*

According to the Group's consolidated financial statements, selected financial performance indicators are presented below.

Income Statement*

In accordance with the Group's consolidated financial statements, selected financial performance indicators are presented below.

Profit & Margins	Q1/2026	Q1/2025
Gross Profit	1.950.843.532	1.083.748.439
Gross Profit Margin	29,5%	21,5%
Operating Prtofit	1.201.526.436	702.323.855
Operating Profit Margin	18,1%	13,9%
EBITDA	1.290.541.508	469.804.580
EBITDA Margin	19,5%	9,3%
Net Profit	374.434.153	413.977.252
Net Profit Margin	5,7%	8,2%

**TAS 29 Financial Reporting Standard in Economies with High Inflation has been applied to these values.*



Balance Sheet*

Assets & Liabilities	31.03.2026	31.03.2025
Total Current Assets	12.024.495.893	10.856.279.041
Total Non-Current Assets	10.285.054.165	10.547.315.578
Total Assets	22.309.550.058	21.403.594.619
Current Liabilities	9.074.378.541	8.554.426.988
Non-Current Liabilities	1.494.435.688	1.482.865.955
Total Liabilities	10.568.814.229	10.037.292.943
Equity	11.740.735.829	11.366.301.676
Current Ratio	1,33	1,27

**TAS 29 Financial Reporting Standard in Economies with High Inflation has been applied to these values.*

7. PROMINENT ACTIVITIES

Details about prominent activities of the Company between January 01, 2026 and Mach 31, 2026 has presented below.

Research and Development Activities

During the period of 01.01.2026 – 31.03.2026, our company's R&D activities were carried out intensively and systematically, in line with our objectives for innovative and generic drug development, regulatory affairs, clinical research, and expansion into international markets. These efforts have further strengthened our company's sustainable growth strategy and scientific competence.

In the first quarter of 2026, the total amount of R&D expenses and investment expenditures incurred within our company was recorded as TRY 70.330.135,60.

Our R&D Center is staffed by an expert team of 31 personnel, 45% of whom are currently pursuing postgraduate studies. This team consists of 2 R&D technicians, 3 R&D analysts, and 26 researchers, conducting innovative and generic drug development activities through a university-industry collaboration approach.

The status of the 27 R&D center projects carried out during this period is as follows:

- 4 projects: Processes are ongoing within the scope of the Technology-Oriented Industrial Move Program.
- 7 projects: Applications have been submitted, and technical evaluation processes are underway.
- 16 projects: Currently in the R&D phase.

Formulation and analytical method development studies continued in the first quarter of 2026 for 11 new projects planned for production at our manufacturing facility under construction in Azerbaijan. 3 of these projects have been made ready for process validation. The remaining projects are targeted for completion within 2026.

GEN Group Companies Elixir İlaç R&D Projects

Elixir İlaç Araştırma ve Geliştirme A.Ş., a subsidiary of GEN İlaç, officially received its R&D Center designation as of February 2026. This status marks a significant milestone in line with the company's high-tech drug development objectives.

Our R&D Center employs an expert team of 20 personnel, 35% of whom are continuing their postgraduate education. The team, comprising 3 R&D technicians and 17 researchers, leads our innovative and generic drug development activities through a university-industry collaboration approach. As of 2026, a total of 16 projects are being carried out by the Elixir R&D team, with 11 focused on the Azerbaijan market and 5 on the Turkish market. During the first quarter of the year, efforts were intensified on analytical validation and method transfer preparations for these projects.

Regulatory Affairs Activities

Within the scope of regulatory activities carried out before the Turkish Medicines and Medical Devices Agency, the R&D processes for 4 projects were completed and finalized ready for submission as of the first quarter of 2026. During the same period, the registration processes for 3 projects were successfully finalized, and technical approval was obtained for 2 products. Additionally, the registration processes for 14 projects are currently ongoing before the relevant authority.

International Market Activities

In line with our international market objectives, registration processes are ongoing for 13 products in the USA and CIS regions, and for 12 products across the Europe, MENA, and Asia-Pacific regions**.**

SUL-238: Alzheimer's Disease Treatment Project

Within the scope of our company's innovation and global growth strategies, the SUL-238 molecule—a potential first-in-class member of its drug category—has reached a strategic clinical stage in the field of neurodegenerative diseases. GEN holds all rights regarding preclinical and clinical research, as well as the manufacturing and commercialization processes of SUL-238.

As previously announced, the Phase 1 (NCT06277492) clinical trial for SUL-238 was successfully completed in healthy volunteers. The formulation development and R&D stability studies of the products used in the clinical trial were conducted at GEN R&D Laboratories, while the production of the clinical trial materials was carried out at the GEN Manufacturing Facility.

Ethical approval has been obtained from the Foundation for the Assessment of Biomedical Research (BEBO) in the Netherlands for the Phase 2 (NCT07322887) Proof of Concept clinical trial, which aims to evaluate the effects of SUL-238 on mitochondrial function in patients with Parkinson's disease. Patient recruitment is scheduled to commence as of April 2026.

Developed by drawing inspiration from natural hibernation mechanisms, SUL-238 possesses an innovative mechanism of action that directly targets the mitochondria—the energy center of the cell. Through the planned Phase 2 and Phase 3 clinical studies, it is intended to slow or halt disease progression by restoring impaired mitochondrial functions, thereby achieving improvement in motor and cognitive functions.

GN-037 Topical Cream Project / "Safe and Effective Drug Formulation for the Treatment of Psoriasis"

For GN-037 topical cream—an innovative investigational drug developed at GEN R&D Laboratories for the treatment of mild-to-moderate plaque psoriasis—a semi-solid production line has been established and successfully commissioned at the GEN Manufacturing Facilities.

The process validation studies for the product have been completed, and the production infrastructure has been rendered ready for clinical and commercial scales. As previously announced, the Phase 1 (NCT05428202) and Phase 2 (NCT05706870) clinical trials of GN-037 have been completed, and preparations are underway to launch our Phase 3 clinical trial in the second half of this year.

The evaluation process for the PCT patent application, filed under the title "Safe and Effective Drug Formulation for the Treatment of Psoriasis," is currently ongoing.

TÜBİTAK and Technology-Oriented Industrial Move Program

The first quarter of 2026 has been a period in which strategic projects within GEN R&D activities were successfully finalized, and reporting processes for next-generation technology investments gained momentum. All projects conducted under the Technology-Oriented Industrial Move Program and the Rising Innovative Technologies Call are progressing in accordance with the planned schedule and budget discipline.

Two of our core projects of strategic importance, which were initiated on 01.04.2023, were successfully completed as of 31.03.2026. In this context, R&D activities for the development of a dual-release tablet formulation containing hydrocortisone for hormone replacement therapy, and the development of a liposomal dosage form containing Amphotericin B for the treatment of systemic mycotic infections, have been concluded as planned. The technical and financial reports for the 2025-2 period of these projects were prepared and submitted to TÜBİTAK in March 2026; the relevant reports are currently in the peer-review evaluation phase.

Two new projects, for which contracts were signed in the second half of 2025, and which will continue until 2027, were among our operational priorities in the first quarter of 2026:

- **Development of an oral treatment product containing methoxsalen for the treatment of psoriasis:** Activities carried out to reduce foreign dependency in this field in Türkiye and to develop domestic treatment options are progressing according to plan. The reporting process for the 2025-2 period has been completed.

- **Development of a new active substance (SUL-238) for the treatment of neurodegenerative diseases:** In the development process of this innovative, mitochondria-targeted molecule for Alzheimer's and Parkinson's diseases, the transition between technical phases was successfully achieved. The technical and financial reports for the 2025-2 period were prepared and submitted to TÜBİTAK in March 2026; the report is currently in the peer-review evaluation phase.

With its strong human capital and projects supported by the Ministry and TÜBİTAK, GEN R&D continues to increase its international competitiveness while contributing to national localization goals.

For the remainder of 2026, the company aims to focus on the commercialization of completed projects and the technical outputs to be derived from ongoing projects.

Registration Activities:

In the period between 01.01.2026 and 31.03.2026, a total of 15 pharmaceutical product licenses were granted, consisting of 6 in Turkey, 4 in Montenegro, 2 in Serbia, 2 in Georgia, and 1 in Kazakhstan. Additionally, license renewals and/or EAEU compliance approvals were obtained for 10 of our products.

19.01.2026- Inclusion in the SSI Reimbursement List for The Drug Named GALAFOLD:

The product named GALAFOLD 123 mg HARD CAPSULES, containing the active ingredient migalastat, manufactured by our licensor AMICUS THERAPEUTICS UK Limited, of which we, Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN), are the marketing authorization holder in Türkiye, has been included in Annex 4/A List of Drugs Subject to Reimbursement by the Social Security Institution (SSI) as of 17.01.2026, and is now reimbursable for "the long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of an amenable mutation of Fabry disease (alpha-galactosidase A deficiency)."

The contribution of this drug to GEN's 2026 sales is expected to exceed TRY 400,000,000.00.

https://www.kap.org.tr/en/Bildirim/1544693

09.02.2026- R&D Center:

According to the letter dated 07.02.2026 from the R&D Incentives Directorate General of the Ministry of Industry and Technology of the Republic of Türkiye, our subsidiary Elixir Pharmaceutical Research and Development Inc. has been granted R&D Center status as of 03.02.2026.

With this status, our subsidiary will be able to benefit from the following deductions, exemptions, supports and incentives under Law No. 5746 on the Support of Research, Development, and Design Activities:

R&D and design deduction, Income tax withholding incentive, Social security premium support, Stamp tax exemption, Customs duty exemption, Support for eligible programs, VAT exemption for the purchase of new machinery and equipment.

https://www.kap.org.tr/en/Bildirim/1554828

23.02.2026- State Supply Office Tender Notification:

Within the scope of the 'January 2026 – 3 Months Pharmaceutical Procurement Tender' participated by Salutem Ecza Deposu Medikal Limited Şirketi (Salutem)—which is an affiliated party of our Company and has been authorized by our Company to sell our pharmaceuticals in tenders organized by the State Supply Office (DMO)—the pharmaceuticals awarded to Salutem will be supplied from our Company.

As a result of the January 2026 – 3 Months DMO tender, the total contribution of the pharmaceuticals awarded to Salutem to GEN's sales will be TRY 652.707.427.

https://www.kap.org.tr/en/Bildirim/1560331

03.03.2026 - Participation in Subsidiary Capital Increase:

The paid-in capital of Gen Pharma Caucasus—in which our company holds a 66.00% stake and which is currently constructing a pharmaceutical manufacturing facility in Azerbaijan—has been increased from 15,300,000.00 Azerbaijani Manat (AZN) to 20,400,000 AZN (12,000,000 USD).

The shareholding rates—which are 66.00% for GEN, 29.00% for the Azerbaijan Business Development Fund (ABİF), and 5.00% for SIA Pharmaceutical have remained unchanged.

https://www.kap.org.tr/en/Bildirim/1565024

16.03.2026- Updates on the SUL-238 Project:

Ethical Board approval has been obtained in the Netherlands for the Phase 2 clinical trial of our innovative drug candidate SUL-238, of which the Phase 1 clinical trial results were announced on December 2, 2025.(https://www.kap.org.tr/en/Bildirim/1521924)

Inspired by hibernation mechanisms observed in animals, our innovative drug candidate SUL-238 has been developed for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. SUL-238 aims to restore mitochondrial dysfunction associated with Parkinson's disease by targeting mitochondria, the energy powerhouses of the cell.

Following the approval granted by the Biomedical Research Ethics Review Foundation (BEBO) in the Netherlands for the Phase 2 Proof of Concept clinical trial, patient recruitment for the study is planned to commence in April 2026.

Abidin Gülmüş, Chairman of GEN, stated: "Following the ethical approval, we look forward to starting patient enrollment in the Netherlands. This Phase 2 trial will be another key milestone toward addressing neurodegenerative diseases at its biological foundation.

https://www.kap.org.tr/en/Bildirim/1572941

8. EMPLOYEE STATUS

As of 31.03.2026, the number of personnel working within the group is 678. The Group's employee distribution is as follows.

Company	Number of Employee
Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş.	551
Genject Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş.	101
Elixir İlaç Araştırma Geliştirme A.Ş.	26
Total	**678**

Gender Distribution



9. LEGAL EXPLANATIONS

Lawsuits and Sanctions

According to the consolidated financial statements as of March 31, 2026 of the amount of provision allocated about Lawsuits which may affect company's financial situation and activities significantly is TRY 15.561.139

10. CHANGE TO THE ARTICLES OF ASSOCIATION MADE DURING THE PERIOD

Within the period of 01.01.2026 – 31.03.2026, the new version of Article 6 of the Company's Articles of Association, titled "Capital", was registered by the Ankara Trade Registry Office on 11.02.2026 and announced in the Turkish Trade Registry Gazette dated 11.02.2026 and numbered 11520.

https://www.kap.org.tr/en/Bildirim/1555821

11. GENERAL ASSEMBLIES HELD DURING THE TERM

The Ordinary General Assembly Meeting of our Company regarding the 2025 fiscal period was held on March 31, 2026. The highlights of the matters discussed at the General Assembly Meeting are summarized below:

At the General Assembly, resolutions were adopted regarding the distribution of the Board of Directors' profit for the 2025 fiscal period, the acceptance of the resignation from the Board of Directors and the approval of the newly elected member to replace the resigned member in accordance with Article 363 of the Turkish Commercial Code (TCC), the selection of the independent audit firm, and the approval of the changes in the Company's headquarters and branch addresses.

The minutes of the General Assembly Meeting can be accessed via the link: https://www.kap.org.tr/tr/Bildirim/1412923.

12. CORPORATE GOVERNANCE PRACTICES

Committees of the Board of Directors

It has been decided by the Board of Directors of the Company to establish the following committees and to determine the memberships as follows.

Committees	Tolga Kızıltan	Bernay Özavcı	Fatih Gören
Audit Committee	Chairman	Member	-
Corporate Governance Committee	Member	Chairman	Member
Early Risk Detection Committee	Member	Chairman	-

The Duties and the Working Principles of the Committees are accessible in our company's corporate website https://www.genilac.com.tr/komite-calisma-usul-ve-esaslari-kurumsal-yonetim/

13. RISK MANAGEMENT PRACTICES

Risk management is implemented in accordance with the policies approved by the board of Directors and in accordance with intermnational standarts. Due to the fact that the sector in which company company operate it is faced with various risks, especially in the financial, operational and legal fields, risks are managed within the framework of the corporate risk management structure with an integrated, systematic and proactive approach with risk assessments updated with processes and spread throughout the organization. With effective risk following, it is provided that prioritization according to effects and possşbilities of these risks and management of these risks corrcectly.

Financial Risks

Within the scope of financial risks, risks arising from uncertainties and fluctuations in exchange rates, interest rates and commodity prices are defined.

When the exchange rate risk is evaluated, although most of our sales are based on imported products, our company does not face a serious exchange rate risk. The purchases and sales of the NPP business line, which constitutes the majority of our company's sales, are in foreign currency in accordance with the contracts made between our company and the relevant institutions, and our company does not carry any exchange rate risk in this field. In the case of imported registered drugs, which have the second largest share in the sales of our company, most of the exchange rate risk has been protected by the contracts signed with the business partners. As a result, our company, which does not carry exchange rate risk in most of its sales. Also, minimizes the exchange rate risk with effective financial management which may arise from the remaining part of the operation. Interest Rate Risk exerts its influence on interest-sensitive assets and liabilities. The negative effects of interest rate risk are eliminated by balancing financial liabilities in short term / long term and fixed interest / variable interest. Uncertainties in commodity prices are minimized with effective stock management.

Liquidity Risk

Liquidity risk is managed by closely monitoring the current cash position and forecasted cash flows, and attention is paid to ensuring maturity matching between assets and liabilities. In order to protect short-term liquidity, net working capital is closely monitored and cash and cash-like assets are held against movements that may occur in the capital markets. In this way, the need for working capital and liquidity risk are minimized. Long-term liabilities are largely held at fixed interest rates and in a flexible structure. Ready-to-use cash and non-cash loan limits are determined with banks.

Risk of Concentration

The majority of the company's revenue comes from the NPP business line. However, with the production facility established in 2017, it is aimed to reduce the NPP concentration. With the registration of the products produced in the production facility and the increase in these products’ sales, it is aimed to eliminate the risk of concentration by reducing the share of the NPP business line in total sales.

Due to the company's extensive operation and customer structure, its receivables are distributed across different sectors and geographical areas. Care is taken not to concentrate in a particular area or client. Trade receivables are monitored with regular reporting and evaluations, and attention is paid to the fact that customer credit risk arising from trade receivables remains within the approved limits. Care is taken to carry out transactions with parties with have credit reliability and to reduce existing risks with the collaterals taken.

Capital Risk

In terms of Capital Risk, the company's goal is to prevent harm to the company and its stakeholders in unexpected situations by continuing its activities with the most appropriate capital structure that reduces the cost of capital while providing returns to its partners. The most important indicators taken into account for this purpose are Net Financial Debt/EBITDA, Total Financial Debts/Equity, Current and Liquidity Ratios, Financial Debt Maturity Structure and Net Working Capital. By ensuring that all these indicators remain within the specified limits, it is seen that the Company has the capital structure and debt capacity to continue its activities in a healthy manner. The Board of Directors is informed by the reports prepared by the Company's management and submitted periodically to the Risk Management Committee.

The Company's issued capital of TRY 4,5 billion is protected by its shareholders' equity of TRY 11.748.972.614 as of March 31, 2026.

Other Risks

Operational, legal and strategic risks are evaluated by the relevant units and the decisions taken by the Senior Management in this field are followed by the Board of Directors through the Risk Management Committee. The Board of Directors also acts proactively with the Early Detection of Risk Committee and Senior management on corporate risk management activities carried out within the scope of strategic planning and management processes.

In order to cover the damages that may arise in the event of operational or other risks including the company and its affliates, insurance is taken out in various issues related to the risks that may occur. All transferrable risks that are transferred to third parties through the insurance process. Operational risks are monitored by the relevant units for the company and periodically reported to the Senior Management.

Changes in the legislation are followed by all relevant units, especially the Legal Counsel's Office, and necessary information, training and compliance activities are carried out to avoid legal risks.

14. STOCK INFORMATION

Ticker ID: GENIL
Bulletin Name: GEN ILAC
Market: BIST STARS
Indices: BIST PARTICIPATION DIVIDEND / BIST 500 / BIST PARTICIPATION 50 /BIST STARS / BIST ANKARA / BIST BUYBACK / BIST DIVIDEND / BIST PARTICIPATION ALL SHARES / BIST W. AND RETAIL TRADE / BIST 100-30 / BIST PARTICIPATION 100 / BIST SERVICES / BIST PARTICIPATION 30 / BIST ALL SHARES / BIST 100
28.03.2025 Price: 9,03[1]
31.03.2026 Price: 10,70[2]
Revenue: 18,49%
One year comperative prices of GENIL with BIST 100 Index has presented below.



[1] *The corrected closing price on 28.03.2025*
[2] *The corrected closing price on 31.03.2026*

16. CONTACT INFORMATION

GEN Investor Relations Department – yatirimciiliskileri@genilac.com

Fatih GÖREN – *Investor Relations Menager*

c.demiralp@genilac.com

0505 177 10 07

Can Onur DEMİRALP – *Investor Relations Specialist*

c.demiralp@genilac.com

0505 177 10 06

Legal Notice

This Activity Report has been prepared in accordance with the legislation in order to inform the shareholders about the company's activities and accounts for the period January 01, 2026 and March 31, 2026. It is not intended to be the basis for any investment decision.

Forward-looking views and estimated numbers reflect company management's views about future situation, realization of these forecasts can vary depending on assumptions and variables which constitutes forward looking numbers. In accordance with this, GEN or its Board of Director Members, advisors or employees are not responsible for any information or communications made in this Report or direct or indirect losses of anybody based on information given in this report or not.

As of the time of preparation of this Activity Report, it is believed that all information in the report is accurate and GEN is not responsible for any inaccuracies that may occur during the spelling and printing stages.

This report has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this report, the Turkish version shall prevail.